Vilanterol Trifenatate + Fluticasone Furoate is a combination medication used for long-term maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD), as well as for once-daily treatment of asthma in adults aged 18 years and older. It contains a selective, long-acting beta-2 agonist (Vilanterol Trifenatate) and a corticosteroid (Fluticasone Furoate), which work together to improve lung function and reduce inflammation in the airways. This medication is not intended for relief of acute bronchospasm.
